Telehealth Reviews

Mochi Health Review 2026: What the Program Actually Costs, and What You Are Buying

By the US Health Digest editorial team · Published August 30, 2026 · Every claim linked to its primary source

Mochi sells a membership; the medicine is billed separately, and almost everything it lists for weight loss is compounded. On joinmochi.com as read on August 30, 2026, membership is $39 for a first month then $79/month, and the footnote says “Medications and diagnostic services not included in membership subscription” (Weight Loss page). Compounded semaglutide starts at $60/month and compounded tirzepatide at $90/month — both lowest-dose figures, with the product pages adding only that “Price varies based on the dose your provider prescribes.” No per-dose price is published anywhere we could find, so the cost at a maintenance dose is not knowable before you pay. Compounded drugs are not FDA-approved, and FDA’s May 2026 proposal not to list semaglutide, tirzepatide or liraglutide for 503B compounding is still pending as of today. US Health Digest has no affiliate or commercial relationship with Mochi Health Corp.

Method: every Mochi figure and quotation below was read on the company’s own live pages on August 30, 2026. Nothing comes from a review site or from customer reviews on Trustpilot, Reddit or app stores — which matters, because Mochi’s comparison pages use Trustpilot stars as a selling point, and unverifiable testimony is what our guide to spotting fake testimonials teaches readers to discount.

What Mochi Health actually is

The structure is in the company’s own terms: a technology company that does not practise medicine, contracting with professional corporations that do. The Terms of Use, “Updated: July 10, 2026,” name Mochi Health Corp., Inc. as the operator and say that “Mochi provides practice management services to Mochi Medical, P.A., a Florida professional corporation, Mochi Medical CA, P.C., a California professional corporation, Mochi Medical KS, P.A., a Kansas professional corporation, and other affiliated medical services providers” (Terms & Conditions). The Patient Agreement lower on the same page names a partly different set — “Mochi Medical, P.C., Mochi Medical CA, P.C., Mochi Medical NJ, P.C., and Mochi Medical KS, P.A.” — “affiliated with Mochi Health Corp., and its affiliates.” Two lists, one page; we report both. The footer draws the line: Mochi Health Corp. “does not provide any professional medical services itself,” and the terms add that “Mochi is not a healthcare provider.” The privacy policy identifies “Mochi Health Corp. (doing business as Join Mochi),” San Francisco.

“board certified obesity medicine providers” — what that means

This is the central positioning: the weight-loss page invites you to “Choose a board certified obesity medicine provider.” The FAQ elaborates: “When you join Mochi, you get access to our board certified obesity medicine providers. Our providers are board certified in several specialties including: Obstetrics and Gynecology, Bariatric Surgery, Internal Medicine, Pediatrics, Family Medicine, Endocrinology, Pediatric Endocrinology, and Cardiothoracic Surgery.” None of those eight is obesity medicine — but the list is expressly partial (“including”), and Mochi’s About page separately describes several of its named physicians as board-certified in obesity medicine alongside family or internal medicine. The claim is not unsupported. The question is who it covers.

The credential the phrase points to is certification by the American Board of Obesity Medicine. For its 2027 and 2028 exam cycles it requires a physician based in the US or Canada, a full unrestricted licence, completed residency, 60 CME credits, an in-person examination and — the load-bearing part — “Active ABMS/AOA board certification” in another specialty first. ABOM states plainly that “Certification is for US and Canadian physicians only” (ABOM, which also flags that its requirements change from the 2028 cycle), and ABOM is not itself one of the 24 ABMS Member Boards. So the credential is real and examined, and physician-only — while the same About page also lists a nurse practitioner and registered dietitians among the clinicians you may be seen by, none of whom could hold it on ABOM’s own stated terms. The marketing plural is “providers”; the credential is narrower than that. Which clinician you are assigned decides whether it applies to you, and ABOM runs a free verification tool to check.

One point in Mochi’s favour: the flow is a scheduled visit, not a form. Step two is “Meet with a doctor over a live 30-minute video visit” — materially different from the asynchronous default in our Hers review, and the most defensible thing Mochi sells. What such a visit should cover: a GLP-1 medical review.

The price, in full

Every figure below was read on Mochi’s own pages on August 30, 2026 and is labelled by price type. All are amounts a patient pays directly; Mochi publishes no insurance-billed or copay figure, and its terms state that “The Monthly Subscription Fee is not a covered benefit under most health insurance plans.” Its cheapest prepaid ladder is offered only “(Available with Qualifying Insurance).” Shipping is not extra (“shipping is included in the medication prices”), but a missed appointment without 24 hours’ notice can draw “a fee of $25.00.”

The arithmetic on those entry prices. Compounded semaglutide at the lowest dose: $99 in month one, then $139 a month, or $1,628 a year. Compounded tirzepatide: $129, then $169, or $1,988. Branded Zepbound: $338, then $378, or $4,496. Membership alone is $908 a year rolling, against a published 12-month prepaid figure for the same plan of $799 on the FAQ page and $548 on the vs-Hers page.

One caveat outweighs all of those totals. The number to judge a program by is the ongoing cost at a maintenance dose, not the introductory offer — and Mochi publishes none. Its per-dose pricing page marks each product “Starting at” one figure and prints the dose ladders (semaglutide 0.22 to 6.48 mg; tirzepatide 2.2 to 16.6 mg) with no price beside any rung (Per Dosage Pricing); the injectable product pages add only that “Price varies based on the dose your provider prescribes.” The one page giving a flat figure, the FAQ, is stale: it quotes the pre-discount price and covers only “0.22mg weekly to 2.67mg weekly,” two rungs short of the advertised ladder. For the doses most people reach, no price is published.

The compounded question, against the regulatory record

Six products are listed on the weight-loss storefront before its “Load More” control, and four are compounded: injectable semaglutide, injectable tirzepatide, a semaglutide pill and orforglipron. Mochi discloses this itself: “Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality.” FDA reports 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, and states that “the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed” (FDA, content current as of 06/15/2026). What turns on it: compounded vs branded GLP-1s in 2026.

The pending federal question is narrow. On May 1, 2026 FDA published a notice (91 FR 23431, Docket FDA-2018-N-3240) that “identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide” (Federal Register). The comment period was extended to July 30, 2026, and a search of that docket today returns no final action. It names three substances, not orforglipron — which matters, because orforglipron was approved as Lilly’s Foundayo™ on April 1, 2026, self-pay from $149 a month for its lowest dose, against Mochi’s compounded version from $31. FDA’s guidance on compounded products that are essentially copies of a commercially available drug is the framework for asking why. See our 2026 compounding tracker and self-pay routes guide.

The warning-letter check. On March 3, 2026 FDA “announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites” (FDA), naming no recipients, so it neither places Mochi on that list nor excludes it. Searching FDA’s Warning Letters database for “mochi,” “Mochi Health” and “joinmochi” on August 30, 2026 returned no letter to any Mochi entity; the only hit is an unrelated 2023 tobacco letter to a company called Mochivap. A checked absence, bounded by what that database indexes.

Which pharmacy? Mochi does not say. Its terms define “Pharmacies” only as “certain third party pharmacies” and warn that “your prescription(s) may be filled by and transferred between any of the Pharmacies”; its pharmacy page invites pharmacies onto a marketplace. Across sixteen Mochi pages we fetched on August 30, 2026, the strings “503A,” “503B” and “outsourcing facility” do not appear once, and no dispensing pharmacy is named. That is a checked absence bounded by those sixteen pages: we did not access Mochi’s app, checkout flow or patient portal, where the answer may well be given. So which pharmacy fills my prescription, and under 503A or 503B? is a question to ask before you pay, not one the public site answers.

What is on the docket. Two brand manufacturers have sued. Eli Lilly and Company filed Eli Lilly and Company v. Mochi Health Corp., No. 3:25-cv-03534 (N.D. Cal.), on April 23, 2025, and Novo Nordisk filed Novo Nordisk A/S v. Mochi Health Corp., No. 5:25-cv-06563 (N.D. Cal.), on August 4, 2025. Both dockets record the cause as trademark infringement under the Lanham Act, 15 U.S.C. 15 U.S.C. 1125sect; 1125, and both name Mochi Health Corp., Mochi Medical P.A. and Mochi Medical CA, P.C. among the defendants; the Lilly docket additionally lists Aequita Corporation and Aequita Pharmacy LLC as co-defendants. We have not read either complaint and make no claim about what either alleges beyond the cause of action recorded on the docket. Read on August 30, 2026, neither docket records a termination, and neither case has been decided. A complaint is an allegation, not a finding. Nothing on either docket establishes that Mochi Health Corp., any Mochi medical group or any co-defendant has done anything unlawful, and being named as a co-defendant does not by itself establish any business or ownership relationship between them.

The marketing claims, beside the trial data

Mochi heads each compounded product with a number. Over compounded tirzepatide: “Average 10–15% body weight loss in 6 months,” footnoted to Hankosky et al. 2025, a retrospective Optum claims study of branded tirzepatide by Eli Lilly employees whose effectiveness cohort averaged 11.9% (Diabetes Obes Metab 2025). Over compounded semaglutide: “Average 15% body weight loss in clinical trials,” footnoted to STEP 1, where semaglutide 2.4 mg averaged 14.9% at 68 weeks against 2.4% on placebo, treatment-policy estimand (NEJM 2021). Both citations are real and neither is misquoted — but both studied the branded products, not the compounded preparations the headlines sit above.

Company-generated figures are a separate category. The comparison page says “10%” weight loss “is achieved in six months for over half of our members” — no method, denominator or source — and says “100,000+ members” while its About page says “500,000+ members” and four medication pages say “500,000+ patients.” Testimonials carry pound figures under the disclosure “These are real mochi members who were compensated for sharing their experiences”; the FTC’s Gut Check guide explains why a compensated before-and-after is not evidence.

Hers vs Mochi, explicitly

Mochi publishes its own version at Mochi Health vs. Hers, updated August 13, 2026, and two of its statements about Hers do not match what Hers itself published. It says “Hers requires a 6-month or 12-month commitment to sign up,” and its table lists Hers membership cost as “No separate membership.” The Hers storefront says the opposite: “An active Hers Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter). Membership is billed separately and does not include or guarantee a prescription” (Internet Archive capture, August 18, 2026). Mochi also prices Hers compounded semaglutide at “$199/month with 12 months paid upfront”; the same capture lists branded products only. One bound on this: forhers.com returns HTTP 403 to automated retrieval, so our Hers reading is that archive capture and is twelve days old, not a live read. It does postdate Mochi’s August 13 update by five days. Both pages may have changed since; check either at source.

Side by side, as of August 30, 2026: Mochi is $39 then $79 a month for membership with mostly compounded medication from $31 to $90 at the lowest doses and branded Zepbound® from $299, and it schedules a live 30-minute video visit; Hers, on the August 18 capture, is $39 then $149 a month with FDA-approved branded medication from $149 and an asynchronous default. Mochi is cheaper and gives you more scheduled clinician time; Hers gives you an FDA-approved product. The compounding question decides between them, not the price. Wider options: our 2026 comparison of GLP-1 telehealth programs for women and Ro vs Noom Med vs Found.

Cancelling and getting money back

The refund position is strict. You cancel in-app or by phone — email is expressly excluded — and “Cancellation of your Paid Membership will take effect at the end of the then current subscription term,” so a prepaid plan runs to its end. On money: “We do not offer refunds for partially used subscription periods,” and “You will not be eligible for a discretionary refund of a Monthly Subscription Fee for any month during which you received services from a Mochi Provider.” For the drug, “Medication Fees… are not eligible for a refund… once the order has been sent to a Pharmacy for dispensing,” and the refunds page says “all prescription sales are final.” Pay, have the visit, and that month is spent whatever happens next.

Questions and answers

How much does Mochi Health cost in 2026?

Read live on joinmochi.com on August 30, 2026: membership is $39 for a first month for new subscribers, then $79 a month, and the storefront footnote states that medications and diagnostic services are not included in the membership subscription. Medication is a separate cash charge: compounded semaglutide from $60 a month, compounded tirzepatide from $90, the compounded semaglutide pill from $62, compounded orforglipron from $31, branded Zepbound from $299. Every one of those is a lowest-dose figure. Mochi publishes no price beside any higher rung of its dose ladders, so the cost at a maintenance dose is not knowable before you pay.

Are Mochi Health’s clinicians board certified in obesity medicine?

Some of the physicians Mochi names are. Its About page, read August 30, 2026, describes several named physicians as board-certified in obesity medicine alongside family or internal medicine. The credential is American Board of Obesity Medicine certification, which ABOM states is “for US and Canadian physicians only” and which requires active ABMS or AOA board certification in another specialty first, 60 CME credits and an in-person examination. ABOM is not one of the 24 ABMS Member Boards. The same About page also lists a nurse practitioner and registered dietitians, who could not hold that credential on ABOM’s stated terms, so the marketing phrase “board certified obesity medicine providers” is broader than the credential itself. ABOM runs a free public verification tool for whichever clinician you are assigned.

We are not telling you to sign up or not to, and nothing here is advice to start, stop or change any medication — that is a conversation with a clinician who knows your history. The documents are listed below. If you are planning a pregnancy in the next year, raise it at the visit. Background: how GLP-1 telehealth works.

Sources